Amsterdam, The Netherlands, December 8, 2004. Agendia BV (Amsterdam, The Netherlands) and the Molecular Profiling Institute (MPI, Phoenix, AZ, USA) announced today that they have reached agreement for distribution of MammaPrint® in the USA. As announced earlier this week, MammaPrint® has successfully reached level 3 in evidence based medicine in an independent international validation under the lead of TRANSBIG, an international translational research network.

“We are very pleased to have MPI as a partner for the USA, which is a key market for Agendia’s MammaPrint®”. “It is important to point out that the potential prospects of the cooperation between Agendia and MPI go much further than expanding the MammaPrint® market to the USA”. “The initial distribution agreement is intended to be expanded into a much broader strategic cooperation, which should allow both parties to join forces in two fields: marketing and sales of their future products and synchronizing their research capabilities, significantly increasing output of new clinically useful products”, said Dr. Bernhard Sixt, Chief Executive Officer of Agendia. “We believe that the MammaPrint® test will provide an important next step for physicians bringing personalized medicine to the nation’s breast cancer patients,” said Robert J. Penny MD, PhD, President and CEO of MPI. “This agreement gives eligible patients in the USA instant access to the latest technology to assess risk of breast cancer progression”, said Prof. Dr. René Bernards, CSO of Agendia. “This is already clinically very relevant today as it will not only allow the identification of a group of high-risk patients that go undetected by the conventional diagnostic tests, but MammaPrint® also adds valuable additional information to cases where conventional diagnostic parameters yield insufficient information.”

About MammaPrint®
Scientists at the Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL) recently identified and validated a 70-gene signature (Van ‘t Veer et. al, Nature, 2002, Van de Vijver et al, N Engl J Med, 2002) that predicts the development of distant metastases in lymph node negative primary breast cancer. This gene signature has been developed into the diagnostic test (MammaPrint®), which is marketed by Agendia BV (Amsterdam, The Netherlands). Under the lead of TRANSBIG, an international translational research network, an independent international validation of Agendia’s MammaPrint® as successfully completed. MammaPrint® outperformed all currently-used standard diagnostic criteria in predicting future development of distant metastases (the development of tumors in other parts of the body) and overall survival in a large breast cancer study.

About Agendia:
Agendia BV is located in Amsterdam the Netherlands and is a company that aims to introduce genomics technologies in the clinical management of cancer. Agendia was formed in July of 2003 as a spin off of the Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL) to allow clinical patients early access to latest research results in the field of gene expression profiling. Agendia uses Agilent Technologies microarrays and has a strong international VC backing with GILDE, GLSV and AXA providing its first round financing in March of 2004.

About MPI:
The Molecular Profiling Institute, Inc. (MPI) is a specialty reference laboratory that helps cancer patients worldwide by applying the discoveries of the Human Genome Project to personalized medicine. MPI provides cutting-edge testing facilities, products, and resources for genomic and proteomic profiling and treatment of cancers. For further information about ordering MammaPrint® in the United States contact MPI at (602) 358-8900 or www.molecularprofiling.com.